Search

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Jun 12 2015 Posted in Press releases

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Program

All session times are in Eastern European Time (EET).

Effective treatment of aging patients with hematological diseases discussed during SWG Aging meeting in Poland

Nov 12 2018 Posted in Meeting reports

The progress in the field of aging and the optimal and rational approaches of "fit" and "unfit" older patients with malignant hemopathies was the focus of the three-day EHA-SWG Scientific Meeting on Aging and Hematology held on October 12-14, 2018 in…

Press release: Work of 2013 Nobel Prize in Physiology or Medicine winners to be presented at the 18th Congress of the European Hematology Association in Stockholm, June 13-16, 2013

Jun 10 2013 Posted in Press releases

With the Scientific Working Group for Stem Cells, the 18th Congress of EHA took the opportunity to acknowledge the work of the 2013 winner of the Nobel Prize for Medicine or Physiology, Drs John B.

Publications

The Reporting, Use, and Validity of Patient-Reported Outcomes in Multiple Myeloma in Clinical Trials: A Systematic Literature Review
Salek, S. ; Ionova, T. ; Oliva, E. N. ; Andreas, M. ; Skoetz, N. ; Kreuzberger, N. ; Laane, E.

Highlights from the SWG

Impactful activitiesGuideline development projectThe most relevant and impactful activities of the SWG include those related to the guideline development project. There were regular meetings with the Guidelines Expert Panel Committee.